1. Sansera Engineering:

This precision components manufacturer rose 6.7% on September 22 after Goldman Sachs maintained its ‘Buy’ rating and raised its target price to Rs 4,990 from Rs 4,500, implying a 7% upside. The brokerage highlighted major investments in India’s semiconductor sector, with Applied Materials committing $5 billion and Lam Research $1.2 billion. Goldman Sachs believes these investments will benefit local suppliers and accelerate growth in Sansera’s high-margin aerospace, defence and semiconductor (ADS) division. 

To move beyond traditional auto parts, Sansera is rapidly growing its ADS business. The company builds high-precision parts for semiconductor manufacturing equipment. In August, a major client awarded Sansera a five-year contract worth Rs 1,250 crore. This deal boosted the company's ADS order backlog by nearly 30% to Rs 5,750 crore, roughly 1.6x its FY26 revenue.

The shift was visible in Q1FY27, when ADS revenue more than tripled YoY to Rs 145.4 crore, nearly half of its FY26 level. Stronger execution and surging exports outside the US and Europe fueled this growth. ADS now drives 14% of Sansera’s revenue, a sharp jump from just 5% in Q1FY26. Commenting on the FY27 outlook, CEO B R Preetham said, “Considering our growth, it will be about 75%-80% in ADS.”

To manage this massive order book, Sansera is expanding its infrastructure. It is building an 80,000-square-foot facility to boost output. The company has also set up an in-house surface-treatment facility, allowing it to finish and treat components internally instead of relying on outside vendors. Management expects this upgrade to speed up deliveries and tighten quality control.

However, execution remains critical. Sansera needs customer approvals before it can start large-scale production and turn its orders into sales. Management says missing an approval deadline can delay production by up to a year. The company also still counts on its legacy auto business for most of its income. Any slowdown in vehicle demand could drag down overall earnings, even as the semiconductor segment surges.

2. Mankind Pharma:

This pharmaceutical company rose 1.7% on Tuesday after Kotak Institutional Equities upgraded its stock to a “Buy” rating from “Add”. The brokerage also raised its target price to Rs 3,000, implying an upside of 22%.

Kotak believes the company's core domestic prescription business is finally recovering after a prolonged restructuring of its sales force. The business accounts for about 80% of overall revenue. One sign of improving demand within this business is sales to pharmacies, which grew 12.7% YoY in the Q1FY27, broadly in line with the Indian pharmaceutical market. The pace picked up over July and August, with growth reaching 14.6%, 1.2 percentage points above the market.

The company is also increasing its focus on chronic drugs, used for long-term conditions such as diabetes and heart disease. Its share of the base domestic business rose to about 40% in Q1. Vice Chairman and MD Rajeev Juneja said, “We remain focused on increasing our chronic share to 50% in the medium term,” while CEO Sheetal Arora said the company expects to get there over the next four to five years. A higher chronic mix, price hikes and a weak base last year helped lift gross margin by 230 basis points to 72.8%.

Kotak expects higher research spending, more launches and stronger volumes to keep the recovery going. The company's 2024 acquisition of Bharat Serums and Vaccines (BSV) expanded its specialty portfolio into areas such as women's health and fertility. BSV grew 21% in Q1, and the company expects high-teens growth this year as it expands in overseas markets and secures approvals in new ones.

The company is also paying down debt taken on for the BSV acquisition. Net debt fell 14% between FY26 and Q1, while finance costs dropped 22.5% sequentially. Global CFO Ashutosh Dhawan said the company remains “on track to repay the acquisition-related debt by FY28.”

The near-term earnings outlook is also strong. Forecaster expects net profit to rise 31.4% in Q2FY27 alongside a 10% increase in revenue. Kotak expects the prescription recovery, higher volumes and new launches to support 23% annual growth in earnings per share through FY29.

3. PB Fintech: 

This insurance distributor’s stock plummeted 38.2% to a 52-week low of Rs 1,115 in two sessions from Thursday. The crash followed the Insurance Regulatory and Development Authority of India's (IRDAI’s) proposal to slash insurance commissions and set strict distribution spending limits to prevent mis-selling. These tighter spending caps will squeeze PB Fintech’s core revenue streams.

The regulator plans commission cuts across key insurance products. New health insurance commissions will drop to 15% from over 30%, while health renewal commissions will fall to 5% from 10-20%. Third-party motor insurance commissions will also plunge to zero from 16%, and own-damage motor commissions will shrink to 5%. As an open-architecture distributor, PB Fintech faces a direct hit to its core earnings from these lower caps.

Management expects no impact on FY27 results but predicts FY28 will be a volatile transition year as the company overhauls its business model to meet the new regulations. PB Fintech said lower distribution commissions could alter the economics of its existing business model and make insurance manufacturing a more relevant option.

Co-founder and CEO Yashish Dahiya notes that the changes will impact the general insurance business, while leaving life insurance largely untouched. He said, “The general insurance segment FY28 revenue is expected to drop to 33-40% of current levels.” However, management believes cost benefits can be partially passed through as volume expansion, with 15-20% growth expected as the business adjusts to the new economics.

To cushion the blow, management will slash marketing expenses rather than staff lay-offs. Dahiya sees room to optimise costs, noting the contact centre generates around 20% of revenue. He anticipates volume growth will demand more tele-calling support to explain complex products and assist with claims.

Brokerages slashed their target prices sharply following the IRDAI proposal. HSBC delivered the deepest cut, downgrading the stock to a ‘Hold’ rating and lowering its target by 45% to Rs 1,150. It slashed FY28 and FY29 earnings estimates by 56% and 17%, respectively, with the impact of lower take rates partly offset by slightly higher volume growth and cost savings. 

Jefferies retained its ‘Buy’ rating but trimmed its target by 24.9%. The brokerage estimates that every 10% drop in new-business commissions will wipe out 10-12% of the company's earnings.

4. Meesho:

The stock of this internet & catalogue retail company rose over 4% in the past week after UBS delivered a positive outlook on the e-commerce platform. Reaffirming its ‘Buy’ rating, the brokerage raised its target price to Rs 260, anticipating stronger medium-term growth and accelerated margin expansion. While keeping its FY27 estimates largely unchanged, UBS bumped up its FY29–FY31 net merchandise value (NMV) and contribution profit projections by 7% to 18%, alongside a major 20% to 40% upward revision in EBITDA estimates.

UBS attributed the sharper boost in EBITDA expectations to expanding operational margins, driven by higher ad monetization and improved delivery economics. Even as management remains confident in its FY27 outlook, analysts noted that shifting Diwali from October 2025 to November 2026 will likely slow Q2 growth before fueling a faster Q3 rebound. The stock appears on a screener for companies that have outperformed their industry over the past month.

Meesho kicked off FY27 on a strong note as Q1 revenue jumped 45.5% YoY to Rs 3,826.4 crore. Boosted by higher merchandise volume, net losses narrowed significantly to Rs 132.8 crore from Rs 289.4 crore in Q1FY26. Cost per delivery decreased by roughly Rs 1 QoQ despite fuel hikes and wage adjustments. Looking ahead, management expects a 25% NMV CAGR through FY31, aiming to nearly double its annual transacting users from 274 million in Q1FY27 to over 500 million over the medium term.

Analysts at Ventura highlighted that India's e-commerce sector remains structurally underpenetrated, offering a massive long-term runway for platforms like Meesho. Online retail currently represents only ~7% of India's retail market, well behind adoption rates seen in Indonesia, the US, and China. However, the brokerage cautioned that aggressive competition or merchant churn could present headwinds to gross merchandise value and overall order growth.

5. Tega Industries:

This mining equipment and consumables maker jumped 10% on Monday after its subsidiary, Tega McNally Minerals, won a Rs 126 crore contract from Kalpataru Projects International. The 14-month contract covers the design, manufacture, supply and commissioning of mineral-processing equipment. Tega makes critical components used in mining and mineral-processing operations, including mill liners, wear-resistant products and conveyor components. These products need to be replaced as they wear down, giving the company a recurring consumables business across global mining markets. 

The bigger change for the business came from Tega’s acquisition of Molycop, which it completed in June at an enterprise value of about $1.5 billion. Molycop is a major supplier of grinding products used in mineral processing, particularly for copper and gold mines. Tega partnered with Apollo Funds for the deal, with Tega holding 84.18% of the acquisition vehicle (joint venture) and Apollo owning the remainder.

Molycop contributed around 75% of group revenue in Q1 despite being consolidated for only one month. On the pro forma financials used when the deal was announced, Molycop accounted for nearly 90% of combined revenue, making it the main revenue driver for the enlarged group.

The next leg of growth could come from cross-selling products through the combined customer network. MD and Group CEO Mehul Mohanka said, “We expect the revenue ramp up to actually happen from Q3 to Q4 onwards of this fiscal year.” Forecaster expects annual revenue to rise more than ninefold in FY27, with net profit growing more than threefold.

Molycop also brings significant debt onto the balance sheet. Its net debt stood at about Rs 6,366 crore at the end of June, down by roughly a third during Q1. Patrick Koley, Chief Financial Officer, Molycop, said the subsidiary’s net debt should decline further by year-end. Tega is also evaluating non-core assets, with proceeds potentially going towards debt repayment.

Tega also expects around $20 million in synergies from combining the two businesses over the next two to three years, mainly through procurement, cost savings and operational efficiencies. The latest analyst consensus tracked by Trendlyne is Hold, reflecting uncertainty around the integration and pace of the earnings ramp-up.

Trendlyne's analysts identify stocks that are seeing interesting price movements, analyst calls, or new developments. These are not buy recommendations.